Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Porcine Epidemic Diarrhea Vaccines Market Size And Revenue Forecast Through 2030
The market for porcine epidemic diarrhea vaccines has experienced robust expansion in recent years. Valued at $1.8 billion in 2025, it is projected to reach $1.94 billion by 2026, reflecting a compound annual growth rate (CAGR) of 7.6%. This historical growth is driven by persistent outbreaks of porcine epidemic diarrhea, elevated mortality among newborn piglets, substantial financial losses within the swine sector, insufficient efficacy from non-vaccine disease management strategies, and a growing dependence on veterinary-directed prevention efforts.
The porcine epidemic diarrhea vaccines market is projected to experience substantial expansion over the coming years, reaching a valuation of $2.5 billion by 2030 with a compound annual growth rate (CAGR) of 6.7%. This anticipated growth in the forecast period is driven by factors such as the rise of intensive pig farming operations, a growing worldwide appetite for pork, heightened recognition of the benefits associated with herd immunity, the enlargement of organized hog production facilities, and supportive governmental initiatives focusing on animal health. Key trends shaping the forecast period encompass a greater uptake of preventive vaccination within swine health management, a heightened preference for live vaccines in regions where the disease is endemic, an increased emphasis on early immunization of piglets, the broadening of vaccination programs within commercial hog farms, and a stronger focus on implementing biosecurity measures and disease control protocols.
Download A Free Sample Report For Comprehensive Market Insights:
Porcine Epidemic Diarrhea Vaccines Market Demand Drivers: What Is Fueling Industry Growth?
Expanding pig farming operations are anticipated to drive growth in the porcine epidemic diarrhea vaccine market moving forward. This type of farming revolves around raising domestic pigs for meat, encompassing breeding, rearing, and managing animals from birth until they reach market weight, as well as producing and selling pork products. This expansion is fueled by rising global pork demand, improvements in breeding techniques and herd management, technological advancements in swine production systems, and the growth of commercial pork markets. Vaccines for porcine epidemic diarrhea (PED) are essential in this context, as they help prevent and control disease outbreaks; they are typically administered during the sow’s gestation period to transfer passive immunity to newborn piglets. As an example, in April 2024, the U.S. Department of Agriculture, a government agency based in the United States, forecasted that U.S. pork production would reach 12.7 million metric tons, indicating increased swine output and supporting ongoing growth in the pig farming industry. Consequently, the rise in pig farming is fueling the expansion of the porcine epidemic diarrhea vaccine market.
Porcine Epidemic Diarrhea Vaccines Market Segmentation Trends And Revenue Drivers
The porcine epidemic diarrhea vaccines market covered in this report is segmented –
1) By Product: Live Vaccines, Killed Vaccines
2) By Application: Piglets, Adults Pigs
3) By End-User: Veterinary Hospitals, Hog Production Farms
Subsegments:
1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines
2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines
Porcine Epidemic Diarrhea Vaccines Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating innovative products like next-generation inactivated and recombinant vaccines to boost immune responses and offer wider protection against new PEDV strains. These advanced vaccines utilize either killed viruses or engineered viral proteins to elicit strong, targeted immunity while improving safety and defending against evolving disease variants. For example, in August 2024, Zoetis Inc., a United States-based animal health company, was awarded a grant for research on the Porcine Epidemic Diarrhea Virus (PEDV) vaccine and also secured a conditional license from the U.S. Department of Agriculture (USDA) for a vaccine designed to combat PEDV in pigs. These initiatives reinforce Zoetis’s position in advancing swine health solutions by enabling further studies, boosting vaccine efficacy, and broadening defense against emerging PEDV strains.
Porcine Epidemic Diarrhea Vaccines Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines
Access The Complete Porcine Epidemic Diarrhea Vaccines Market Report:
Porcine Epidemic Diarrhea Vaccines Market Leading Geography: Which Region Generates The Most Revenue?
Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model